Roche Prepares Faricimab For Filing After Phase III AMD Data
Non-Inferior To Eylea With Longer Dosing Intervals
Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.
